Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we predict Crohn's damage before it happens? a Long-Term study aims to find out

NCT ID NCT05420233

Knowledge-focused Sponsor: GLSMED Learning Health S.A. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This study follows people newly diagnosed with Crohn's disease for up to five years to see how the condition damages the bowel over time. Researchers will use imaging scans and other tests to track disease progression and understand how different treatments affect long-term outcomes. The goal is to develop better ways to predict and prevent permanent bowel damage.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors predict which treatments best prevent long-term bowel damage in Crohn's disease.
What could go wrong
This is an observational study, not a treatment trial, so it will not directly test a new therapy. Results depend on careful follow-up over many years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

533 people

The number who actually took part.

Started

Aug 2021

Expected to finish

Jul 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

INCLUSION CRITERIA To be eligible all of the following criteria must be met: * Diagnosis of CD (according to ECCO guidelines) established within the past 12 months; * Patients able to understand the information provided to them and to give written informed consent for the study; * Male or female, age \> 18 years. EXCLUSION CRITERIA: * Patients unwilling or unable to provide informed, written consent; * Severe underlying medical disorder with an anticipated life expectancy \< 2 years; * Refusal or medical conditions (e.g. Glomerular filtration rate \< 30 mL/min) preventing cross-sectional imaging during follow-up; * Uncertain CD diagnosis; * Pregnancy (if it is impossible to implement the MRE at one year) or any other reason that makes resonance not feasible throughout the study (eg claustrophobia).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Crohn disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Crohn disease

Contacts and locations

Locations

  • Algomed Policlinic

    Timișoara, Romania

  • American Gastroenterology Center

    Stróvolos, Cyprus

  • Azienda Ospedaliera di Padova

    Padova, Italy

  • CHU Amiens-Picardie Hôpital Sud

    Amiens, France

  • CHU Estaing Clermont - Ferrand

    Clermont-Ferrand, France

  • Claude Huriez Hospital, Lille University

    Lille, France

  • Hospital Alvaro Cunqueiro - Área Sanitária de Vigo

    Vigo, Spain

  • Hospital Beatriz Angelo

    Loures, Loures, Portugal

  • Hospital Clinic Barcelona

    Barcelona, Spain

  • Hospital Galdakao-Usansolo

    Galdakao, Spain

  • Hospital Garcia da Orta

    Almada, Almada, Portugal

  • Hull University Teaching Hospitals NHS Trust

    Hull, United Kingdom

  • Hvidovre Hospital

    Hvidovre, Denmark

  • IBD Clinical and Research Clinic, ISCARE

    Prague, Czechia

  • Instituto Portugues de Oncologia de Lisboa

    Lisbon, Lisbon District, Portugal

  • Mater dei hospital

    Msida, Malta

  • Slagelse Hospital

    Slagelse, Denmark

  • St Mark's Hospital

    London, United Kingdom

  • University Hospital CHU of Liège

    Liège, Liège, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.